Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

Completed · Phase 1 · Has a placebo group

Conditions studied: Hyperuricemia, Gout

In brief

The purpose of this Phase I study is to evaluate the safety and tolerability of ALLN-346 in in normal healthy volunteers, in an ascending dose design. ALLN-346 is an (oral) enzyme that specifically degrades urate in the intestinal tract.

Key facts

Study ID
NCT04829435
Run by
Allena Pharmaceuticals
People needed
18
Starts
2021-04-21
Expected to finish
2021-06-01
Last updated by the study team
2021-07-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.